{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:16:49Z","timestamp":1758478609435,"version":"3.37.3"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The current study evaluates survival rates among SSc-associated pulmonary arterial hypertension (SSc-PAH) patients on i.v. prostanoids, and short-term impact of i.v. prostanoids on clinical and haemodynamic parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Baseline demographics, invasive and non-invasive data, European Society of Cardiology (ESC) score and REVEAL score of 81 SSc-PAH patients (median age 61\u2009years, interquartile range 54\u201367\u2009years, 84% females) were prospectively recorded, from November 2006 till November 2020, before initiation of i.v. prostanoids, and at first formal reassessment. Survival data were retrieved from National Health Service Spine and hospital databases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Significant improvements in clinical and haemodynamic parameters in response to i.v. prostanoid therapy were documented. Functional class (FC) (16.6% improved by 1FC, P =0.041), mean pulmonary arterial pressure (\u22126.5\u2009mmHg, P =0.036), pulmonary vascular resistance (\u22122.6 WU, P =0.012), cardiac index (Q\/m2) (+0.7\u2009l\/min\/m2, P =0.003) and mixed venous oxygen saturation (SvO2) (+3%, P =0.036) improved. Estimated survival for CTD-PAH patients on i.v. prostanoids was 64%, 31% and 18%, at 1 year, 3 years and 5 years, respectively. Independent baseline predictors of mortality were older age (HR: 1.043, 95% CI: 1.011\u20131.075, P =0.007), higher N-terminal pro-brain natriuretic peptide levels (HR: 2.191, 95% CI: 1.131\u20134.243, P =0.020), and lower SvO2 levels (HR: 0.962, 95% CI: 0.926\u20130.998, P =0.039). High ESC risk or high and very high REVEAL score was associated with significantly worse survival compared with patients with lower risk scores, both at baseline and when reassessed after a median of 6.5\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Survival among SSc-PAH patients on i.v. prostanoids remains poor, risk scoring at baseline and after 6.5 months of therapy improves prognostication.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab478","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T11:08:44Z","timestamp":1623755324000},"page":"1106-1114","source":"Crossref","is-referenced-by-count":4,"title":["Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: a single-centre experience"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4369-1644","authenticated-orcid":false,"given":"Maria","family":"Vlachou","sequence":"first","affiliation":[{"name":"National Pulmonary Hypertension Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam","family":"Fayed","sequence":"additional","affiliation":[{"name":"National Pulmonary Hypertension Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Dawson","sequence":"additional","affiliation":[{"name":"National Pulmonary Hypertension Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Reddecliffe","sequence":"additional","affiliation":[{"name":"National Pulmonary Hypertension Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Stevenson","sequence":"additional","affiliation":[{"name":"National Pulmonary Hypertension Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross J","family":"Thomson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal Free Hospital"},{"name":"William Harvey Research Institute, Queen Mary, University of London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Emmanuel","family":"Schreiber","sequence":"additional","affiliation":[{"name":"National Pulmonary Hypertension Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Gerry","family":"Coghlan","sequence":"additional","affiliation":[{"name":"National Pulmonary Hypertension Unit"},{"name":"Department of Cardiology, Royal Free Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"2022030208033511200_keab478-B1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"2022030208033511200_keab478-B2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","article-title":"Pulmonary arterial hypertension: the clinical syndrome","volume":"115","author":"Lai","year":"2014","journal-title":"Circ Res"},{"key":"2022030208033511200_keab478-B3","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2022030208033511200_keab478-B4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.41669","article-title":"Long-term outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era: meta-analyses of randomized, controlled trials and observational registries","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022030208033511200_keab478-B5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-0039-1685214","article-title":"Pulmonary hypertension associated with connective tissue disease","volume":"40","author":"Fayed","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"2022030208033511200_keab478-B6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"Conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"2022030208033511200_keab478-B7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"2022030208033511200_keab478-B8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2022030208033511200_keab478-B9","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.3899\/jrheum.081277","article-title":"Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol","volume":"36","author":"Badesch","year":"2009","journal-title":"J Rheumatol"},{"key":"2022030208033511200_keab478-B10","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022030208033511200_keab478-B11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/resp.12899","article-title":"Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension","volume":"22","author":"Ramjug","year":"2017","journal-title":"Respirology"},{"key":"2022030208033511200_keab478-B12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.chest.2018.03.050","article-title":"Mortality in patients with pulmonary arterial hypertension treated with continuous prostanoids","volume":"154","author":"Bartolome","year":"2018","journal-title":"Chest"},{"key":"2022030208033511200_keab478-B13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.healun.2019.05.002","article-title":"Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension","volume":"38","author":"Olsson","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2022030208033511200_keab478-B14","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"Van Den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022030208033511200_keab478-B15","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2022030208033511200_keab478-B16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"2022030208033511200_keab478-B17","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022030208033511200_keab478-B18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/ard.2010.143792","article-title":"The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients","volume":"70","author":"Gunnarsson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022030208033511200_keab478-B19","first-page":"23","volume-title":"Mixed connective tissue diseases and anti-nuclear antibodies","author":"Sharp","year":"1987"},{"key":"2022030208033511200_keab478-B20","first-page":"33","volume-title":"Mixed connective tissue diseases and anti-nuclear antibodies","author":"Alarc\u00f3n-Segovia","year":"1987"},{"key":"2022030208033511200_keab478-B21","first-page":"41","volume-title":"Mixed connective tissue diseases and anti-nuclear antibodies","author":"Kasukawa","year":"1987"},{"key":"2022030208033511200_keab478-B22","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1093\/rheumatology\/kex351","article-title":"Prognostic significance of computed tomography criteria for pulmonary veno-occlusive disease in systemic sclerosis-pulmonary arterial hypertension","volume":"56","author":"Connolly","year":"2017","journal-title":"Rheumatology"},{"key":"2022030208033511200_keab478-B23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"2022030208033511200_keab478-B24","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur Heart J"},{"key":"2022030208033511200_keab478-B25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.510300307","article-title":"Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension","volume":"30","author":"Krowka","year":"1999","journal-title":"Hepatology"},{"key":"2022030208033511200_keab478-B26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijcard.2013.12.313","article-title":"Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry","volume":"172","author":"Bergot","year":"2014","journal-title":"Int J Cardiol"},{"key":"2022030208033511200_keab478-B27","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0735-1097(99)00320-4","article-title":"The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension","volume":"34","author":"Rich","year":"1999","journal-title":"J Am Coll Cardiol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab478\/39309908\/keab478.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/1106\/42672017\/keab478.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/1106\/42672017\/keab478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T08:06:19Z","timestamp":1646208379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/3\/1106\/6303623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6,17]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab478","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,6,17]]}}}